Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has announced several executive management changes.
 
First, Lars Staal Wegner has decided to resign as the company’s Chief Executive Officer. Wegner will remain with the company in an advisory role to the company’s new CEO and Board of Directors.
 
In Wegner’s place, the company has appointed Per Norlén, M.D., PhD., a physician and board-certified specialist in Clinical Pharmacology with extensive research experience and over 20 years of working in clinical drug development and management within biopharmaceutical industry.
 
“We are very pleased that Per Norlén has accepted the role as CEO of Evaxion. Onboarding a new CEO is part of our plans to have broader qualified management to take us to the next level in future consolidation of the projects and pursue new and strong partnerships, among others. Per has a vast experience in the field of oncology as well as CEO experience from listed and unlisted companies. We are confident that Per is the right person to bring Evaxion into the future to benefit shareholders, employees, and most importantly, patients,” said Marianne Soegaard, Chairman of the Board.

About Dr. Norlén

Most recently, Norlén was Chief Executive Officer of Targinta AB and Chief Medical Officer of Xintela AB, Targinta is a wholly owned subsidiary of Xintela, a publicly listed company on the Nasdaq First North Growth Market Stockholm, Sweden. 
 
Before that, Norlén was the Chief Executive Officer and Chief Medical Officer at Alligator Bioscience AB, a publicly listed company on the Nasdaq Stockholm market.
 
Norlén holds an M.D. and a PhD. in Clinical Pharmacology from Lund University, where he is an Associate Professor of Experimental and Clinical Pharmacology. Norlén will take over from Wegner as the Company’s CEO within the next six months.
 
“I am looking forward to taking on the role as CEO for Evaxion Biotech, deep diving into a business field merging AI-technology and next-generation personal immunotherapies,” Norlén commented. “Evaxion holds an ambitious aspiration to fundamentally change drug development, ultimately saving patients’ lives. I share that aspiration and  look forward to contributing to the endeavor together with the great people at Evaxion.”
 
“After ten great years at Evaxion, I am happy to leave the seat to Per, and I am proud of what we as a company have accomplished in that time. Evaxion is in good shape and has a solid foundation of cutting-edge technology and world-class scientific expertise. As the company takes the next leap, it is time for others to take over. Per has the right profile and brings the expertise and background to grow our great company even further, and I plan to be there along the way to support Per and the company moving forward,” said Wegner.